Lantern Pharma Inc. (LTRN) Form S-1 — Jun 12, 2026
Lantern Pharma Inc. (LTRN) filed an S-1 registration statement to register 2,242,719 shares of common stock issuable upon the exercise of warrants held by selling stockholders. The company will not receive any proceeds from the resale of these shares by the selling stockholders, though it may receive approximately $5.1 million if the warrants are exercised for cash. The filing highlights significant financial risks, noting that the company had $6.3 million in cash and equivalents as of March 31, 2026, following a $4.4 million registered direct offering in May 2026.
Key figures
- Total Assets
- 7200000
- Cash Position
- 6300000
- Offering Price
- 3.9
- Shares Offered
- 2242719
- Working Capital
- 3300000
- Recent Financing Proceeds
- 4400000
- Shares Outstanding
- 12759146
- Pre Funded Warrant Price
- 2.0599
- Warrant Exercise Price1
- 2.27
- Warrant Exercise Price2
- 2.575
- Stock Price Last Reported
- 4.07
- Common Stock Offering Price
- 2.06
Price after filing
Close on the filing date to close N calendar days later (from $4.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.